NeoGenomics Inc NEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
-
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
-
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
-
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
-
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
-
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
-
NeoGenomics to Participate in Upcoming Investor Conferences
-
NeoGenomics Reports First Quarter 2026 Results
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 130.21M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 111.54
- Price/Sales
- 2.50
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.02%
Company Profile
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,500
- Website
- https://www.neogenomics.com
Valuation
|
Metric
|
NEO
|
|---|---|
Price/Earnings (Normalized) | 111.54 |
Price/Book Value | 2.27 |
Price/Sales | 2.50 |
Price/Cash Flow | 42.87 |
Price/Earnings
NEO
Financial Strength
|
Metric
|
NEO
|
|---|---|
Quick Ratio | 3.71 |
Current Ratio | 4.42 |
Interest Coverage | −38.81 |
Quick Ratio
NEO
Profitability
|
Metric
|
NEO
|
|---|---|
Return on Assets (Normalized) | 1.18% |
Return on Equity (Normalized) | 1.96% |
Return on Invested Capital (Normalized) | 0.99% |
Return on Assets
NEO
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|#r^#d<J | LOCK|%X! | $199B | |||
| Danaher Corp
DHR
| LOCK|pg?XNz!F | LOCK|mg | $142B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|#B#<H@h | LOCK|jkW | $44B | |||
| Agilent Technologies Inc
A
| LOCK|R<CDy^R | LOCK|?%r | $38B | |||
| Waters Corp
WAT
| LOCK|#^k>BB | LOCK|F% | $37B | |||
| IQVIA Holdings Inc
IQV
| LOCK|F$FXDb^ | LOCK|hdf?z | $35B | |||
| Illumina Inc
ILMN
| LOCK|$?&dg& | LOCK|C>$# | $28B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|m$$rT^?? | LOCK|G%l>% | $27B | |||
| Quest Diagnostics Inc
DGX
| LOCK|%@Jv>g | LOCK|d^N&@ | $22B | |||
| Labcorp Holdings Inc
LH
| LOCK|<b^@L!kB | LOCK|pfw@! | $22B |
United States